The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

NCT00716092 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo (linagliptin)
DRUG: Placebo (linagliptin)
DRUG: Sitagliptin
DRUG: Placebo (sitagliptin)
DRUG: Placebo (sitagliptin)
DRUG: Linagliptin

Sponsor

Boehringer Ingelheim